LGALS4
Galectin-4
Also known as: GAL4, LEG4_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P56470
- Gene
- LGALS4
- Ensembl
- ENSG00000171747
- Chromosome
- 19
- Canonical length
- 323 aa
- Protein class
- Cancer-related genes, Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Plasma membrane
OverviewNCBI Gene
The galectins are a family of beta-galactoside-binding proteins implicated in modulating cell-cell and cell-matrix interactions. The expression of this gene is restricted to small intestine, colon, and rectum, and it is underexpressed in colorectal cancer. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
323 residues, UniProt reviewed canonical sequence.
>P56470|LGALS4
1 MAYVPAPGYQ PTYNPTLPYY QPIPGGLNVG MSVYIQGVAS EHMKRFFVNF VVGQDPGSDV
61 AFHFNPRFDG WDKVVFNTLQ GGKWGSEERK RSMPFKKGAA FELVFIVLAE HYKVVVNGNP
121 FYEYGHRLPL QMVTHLQVDG DLQLQSINFI GGQPLRPQGP PMMPPYPGPG HCHQQLNSLP
181 TMEGPPTFNP PVPYFGRLQG GLTARRTIII KGYVPPTGKS FAINFKVGSS GDIALHINPR
241 MGNGTVVRNS LLNGSWGSEE KKITHNPFGP GQFFDLSIRC GLDRFKVYAN GQHLFDFAHR
301 LSAFQRVDTL EIQGDVTLSY VQILocalizationUniProt · AlphaFold · HPA
Whether an antibody against LGALS4 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.28
- Highest tissue expression
- 1,827 nTPM
Expression across tissuesHPA
Tissue
- colon: 1,827 nTPM
- rectum: 876 nTPM
- small intestine: 837 nTPM
- duodenum: 764 nTPM
- gallbladder: 129 nTPM
- stomach: 128 nTPM
Single-cell type
- colonocytes: 5,487 nCPM
- goblet cells: 3,764 nCPM
- enteric transient amplifying cells: 3,293 nCPM
- enterocytes: 3,039 nCPM
- enteric stem cells: 2,115 nCPM
- paneth cells: 975 nCPM
Immune cell
- basophil: 0.2 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebellum: 0.9 nTPM
- cerebral cortex: 0.8 nTPM
- white matter: 0.7 nTPM
- basal ganglia: 0.6 nTPM
- thalamus: 0.6 nTPM
- hippocampal formation: 0.5 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.08
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.64
- DepMap mean gene effect
- 0.01
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads LGALS4 as an antibody target. Whether an autoantibody or antibody against LGALS4 could matter depends on whether native LGALS4 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
LGALS4 is annotated at the cell surface, where native LGALS4 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label LGALS4 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...